|
|
4301 West Markham, # 831
Little Rock, AR 72205-7199 USA
phone:(501) 296 1254
fax:
|
|
| Symbol |
Private |
| Founded |
2003 |
| Employees |
4 |
|
|
| www.dcvtech.net
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Development of therapeutic vaccines for the treatment of cancer. |
|
| Management |
| CEO-Martin Cannon, Ph.D. |
| |
|
|
| |
|
| Keywords |
| therapeutic vaccines, cancer, dendritic cell vaccines, DC vaccines, gynecological malignancy vaccine, prostate cancer vaccine, antigens, |
|
|
|
| Description |
|
DCV Technologies, Inc. is dedicated to the development of therapeutic vaccines for the treatment of cancer, based on core technologies developed at the University of Arkansas for Medical Sciences (UAMS). |
|
| Products / Services |
Antigens licensed by DCV and the diseases in which they are expressed:
- TADG-14-Ovary, Cervix, Breast, Colon
- TADG-14 Variant-Ovary, Cervix, Breast, Colon
- TADG 15-Ovary, Prostate, Breast, Lung
- TADG 12-Ovary, Breast
- TADG 12 Variant D-Ovary, Breast
- TADG 12 Variant V-Ovary, Breast
- Hepsin-Ovary, Prostate, Lung
- Hepsin Variant-Ovary, Prostate, Lung
- SCCE-Ovary, Pancreatic, Colon
- ALP-Ovary, Lung
- MMP7-Ovary, Prostate, Colon , Lung
- TADG7-Ovary
- CA125-Ovary
|
|
| Technology / Differentiation |
- Exclusively licensed rights to 14 known tumor antigens expressed by cancers of the reproductive tract and breast cancer.
- Patent portfolio includes 14 domestic patents, 6 foreign patents, and 31 pending filings.
- License includes the first rights to license new technology in the field of cancer vaccines from UAMS.
- Sound process for producing dendritic cell-based vaccines has been developed.
- Vaccines show high selectivity for attacking targeted diseases.
Our vaccines exhibit low toxicity, minimal side-effects and higher quality of life
|
|
| Market / Customers |
In the United States:
- Approximately 25,000 new cases of ovarian cancer are diagnosed annually.
- 40,880 new cases of endometrial cancer were projected to occur in 2005.
- It is estimated that, the market for cancer vaccines will increase substantially from to nearly $1.3 billion in 2008./
-
|
|
| Competitors / Substitutes / Alternatives |
Cancer vaccines are currently offered for only a limited number of cancers that affect people worldwide.
The approved vaccines have offered additional choices to victims of cancer and have shown favorable results in a significant number of treated patients.
The cancers with currently approved and marketed vaccines include bladder, colorectal, and melanoma.
Dendrion is currently completing clinical trials in prostrate cancer with encouraging early results.
|
|
| Strategy |
DCV Technologies, Inc. is focused on leveraging proprietary technologies and developing key collaborative agreements to advance the development and clinical testing of therapeutic vaccines.
|
|
| Funding |
A Small Business Technology Transfer grant from the National Cancer Institute and sponsorship from the Arkansas Science and Technology Authority has supported preclinical testing of a second generation, enhanced DC vaccine for ovarian cancer.
DCV is actively seeking funding to further its preclinical research program and to advance its therapeutic vaccine products through Phase I and Phase II clinical trials. |
|
| Status |
DCV's technology has successfully completed a Phase I trial for cervical cancer.
Preclinical work for vaccines for prostate and ovarian cancers and are seeking FDA approval for Phase I trials of these dendritic vaccines. |
|
|
|
| |
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members